Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid

The Journal of Clinical Endocrinology and Metabolism
Rossella EliseiAldo Pinchera

Abstract

One of the major limits of gene therapy with sodium iodide symporter (NIS), which enables cells to be subjected to radioiodine therapy, is that NIS-transfected cells rapidly release the intracellular iodine. We transfected human anaplastic (FRO) and medullary (TT) thyroid cancer-derived cell lines that were unable to take up iodine with human NIS cDNA. The possibility of increasing the iodine retention time by treating the transfected clones with myricetin, lithium, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) was explored. We obtained 19 FRO and 16 TT clones stably transfected with NIS. Twelve of 19 FRO and nine of 16 TT clones expressed the full-length NIS mRNA; 11 of 12 FRO and four of nine TT clones were able to take up radioiodine and correctly expressed NIS protein on the plasma membrane. Kinetic analysis of iodide uptake in the two clones (FRO-19 and TT-2) with the highest uptaking activity revealed that the plateau was reached after 30 min by FRO-19 and after 60 min by TT-2. The t(1/2) of the iodide efflux was 9 min in FRO-19 and 20 min in TT-2. The treatment of the two cell lines with four different drugs revealed that DIDS and 17-AAG, but not myriceti...Continue Reading

Citations

Oct 12, 2012·Endocrine·Rossella Elisei
Mar 28, 2013·Thyroid : Official Journal of the American Thyroid Association·Mariateresa PuglieseMaria Graziella Catalano
Jul 24, 2010·AJR. American Journal of Roentgenology·Alan R PenheiterStephanie K Carlson
Dec 1, 2012·Nuclear Medicine and Molecular Imaging·Kyoung Hyun YuJune-Key Chung
Sep 15, 2007·Surgical Oncology·David Yü Greenblatt, Herbert Chen
Aug 4, 2007·Endocrinology and Metabolism Clinics of North America·Priya Kundra, Kenneth D Burman
May 6, 2011·Head & Neck·Cesar A PerezEzra E W Cohen
Mar 24, 2016·Pharmaceutical Research·Raphaël PaweloszekMarie-Alexandrine Bolzinger
Mar 27, 2016·Pharmaceutical Research·Raphaël PaweloszekMarie-Alexandrine Bolzinger
Mar 5, 2013·Toxicology in Vitro : an International Journal Published in Association with BIBRA·AlberTinka J MurkArno C Gutleb
Sep 25, 2007·Arquivos brasileiros de endocrinologia e metabologia·Denise P Carvalho, Andrea C F Ferreira
Sep 26, 2009·ChemMedChem·Nathalie Lecat-Guillet, Yves Ambroise
Sep 28, 2014·The Oncologist·Kun-Tai HsuHerbert Chen
Nov 22, 2019·Frontiers in Oncology·Shilpa ThakurJoanna Klubo-Gwiezdzinska

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.